JP2013529183A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013529183A5 JP2013529183A5 JP2013502691A JP2013502691A JP2013529183A5 JP 2013529183 A5 JP2013529183 A5 JP 2013529183A5 JP 2013502691 A JP2013502691 A JP 2013502691A JP 2013502691 A JP2013502691 A JP 2013502691A JP 2013529183 A5 JP2013529183 A5 JP 2013529183A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- antibody
- sequence
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 3
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 238000011394 anticancer treatment Methods 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 229940022353 herceptin Drugs 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 238000011269 treatment regimen Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31989610P | 2010-04-01 | 2010-04-01 | |
| US61/319,896 | 2010-04-01 | ||
| PCT/US2011/030148 WO2011123381A1 (en) | 2010-04-01 | 2011-03-28 | Antibodies against csf-1r |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013529183A JP2013529183A (ja) | 2013-07-18 |
| JP2013529183A5 true JP2013529183A5 (enExample) | 2013-12-05 |
| JP5767310B2 JP5767310B2 (ja) | 2015-08-19 |
Family
ID=44010222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013502691A Expired - Fee Related JP5767310B2 (ja) | 2010-04-01 | 2011-03-28 | Ｃｓｆ−１ｒに対する抗体 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8263079B2 (enExample) |
| EP (2) | EP2552966B1 (enExample) |
| JP (1) | JP5767310B2 (enExample) |
| KR (1) | KR101439719B1 (enExample) |
| CN (1) | CN102834414B (enExample) |
| AR (1) | AR080698A1 (enExample) |
| AU (1) | AU2011232850B2 (enExample) |
| BR (1) | BR112012024564A2 (enExample) |
| CA (1) | CA2795081C (enExample) |
| CY (1) | CY1119324T1 (enExample) |
| DK (1) | DK2552966T3 (enExample) |
| EA (1) | EA021600B1 (enExample) |
| ES (1) | ES2640909T3 (enExample) |
| HR (1) | HRP20171153T1 (enExample) |
| HU (1) | HUE036379T2 (enExample) |
| IL (1) | IL222222A (enExample) |
| JO (1) | JO3291B1 (enExample) |
| LT (1) | LT2552966T (enExample) |
| ME (1) | ME02806B (enExample) |
| MX (1) | MX2012011234A (enExample) |
| NZ (1) | NZ602621A (enExample) |
| PL (1) | PL2552966T3 (enExample) |
| PT (1) | PT2552966T (enExample) |
| RS (1) | RS56219B1 (enExample) |
| SG (1) | SG183829A1 (enExample) |
| SI (1) | SI2552966T1 (enExample) |
| TW (1) | TWI402078B (enExample) |
| UA (1) | UA111818C2 (enExample) |
| WO (1) | WO2011123381A1 (enExample) |
| ZA (1) | ZA201206926B (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010329934B2 (en) | 2009-12-10 | 2015-05-14 | F. Hoffmann-La Roche Ag | Antibodies binding preferentially human CSF1R extracellular domain 4 and their use |
| WO2017120461A1 (en) | 2016-01-08 | 2017-07-13 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| US20160208011A1 (en) | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| US10487148B2 (en) | 2010-01-28 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated impairments |
| CA2789071C (en) | 2010-03-05 | 2018-03-27 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| MX2012010014A (es) | 2010-03-05 | 2012-09-21 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| MX355418B (es) | 2010-05-04 | 2018-04-18 | Five Prime Therapeutics Inc | Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r). |
| US9161968B2 (en) | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
| US10023643B2 (en) | 2011-12-15 | 2018-07-17 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R and uses thereof |
| EP2812355A4 (en) * | 2012-02-06 | 2016-03-02 | Hoffmann La Roche | COMPOSITIONS AND METHODS OF USE OF CSF1R INHIBITORS |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| SG10201906328RA (en) | 2012-08-31 | 2019-08-27 | Five Prime Therapeutics Inc | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| AR095882A1 (es) | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| GB201315487D0 (en) | 2013-08-30 | 2013-10-16 | Ucb Pharma Sa | Antibodies |
| AR097584A1 (es) * | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| EA035336B1 (ru) | 2013-12-09 | 2020-05-29 | Зе Боард Оф Трастиз Оф Зе Леланд Стэнфорд Джуниор Юниверсити | Способ лечения связанного со старением когнитивного расстройства или заболевания |
| US10905779B2 (en) | 2013-12-09 | 2021-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening human blood products comprising plasma using immunocompromised rodent models |
| KR102000224B1 (ko) * | 2014-02-03 | 2019-07-16 | 전대연 | 스마트 이메일 관리방법 |
| KR20230086809A (ko) | 2014-06-23 | 2023-06-15 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체 (ｃｓｆ1ｒ)에 결합하는 항체를 이용하여 병태를 치료하는 방법 |
| BR112017008914A2 (pt) | 2014-10-29 | 2018-01-16 | Five Prime Therapeutics, Inc. | método para tratar câncer, composição e uso da composição |
| KR20170096187A (ko) | 2014-12-22 | 2017-08-23 | 파이브 프라임 테라퓨틱스, 인크. | Pvns를 치료하기 위한 항-csf1r 항체 |
| CN107709365A (zh) | 2015-04-13 | 2018-02-16 | 戊瑞治疗有限公司 | 癌症组合疗法 |
| CN113940996A (zh) | 2015-05-27 | 2022-01-18 | Ucb生物制药私人有限公司 | 用于治疗神经系统疾病的方法 |
| AU2016279804B2 (en) | 2015-06-15 | 2019-03-07 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated conditions |
| JP6621252B2 (ja) * | 2015-06-17 | 2019-12-18 | 国立大学法人北海道大学 | 治療耐性がんに対する治療耐性低減剤 |
| EP3108897A1 (en) | 2015-06-24 | 2016-12-28 | F. Hoffmann-La Roche AG | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias |
| US20180222985A1 (en) * | 2015-06-24 | 2018-08-09 | Hoffmann-La Roche Inc. | Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias |
| EP3973988A1 (en) | 2015-11-04 | 2022-03-30 | Duke University | Combination therapy of immunotoxin and checkpoint inhibitor |
| WO2017085566A1 (en) * | 2015-11-20 | 2017-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for increase/induction of immune responses |
| US20180291107A1 (en) * | 2015-11-24 | 2018-10-11 | Eli Lilly And Company | Combination therapy for cancer |
| CA3005932A1 (en) * | 2015-11-25 | 2017-06-01 | Nogra Pharma Limited | Il-34 antisense oligonucleotides and methods of using same |
| WO2017189919A2 (en) | 2016-04-28 | 2017-11-02 | Alkahest, Inc. | Blood plasma and plasma fractions as therapy for tumor growth and progression |
| TWI640536B (zh) | 2016-06-20 | 2018-11-11 | 克馬伯有限公司 | 抗體 |
| US10525107B2 (en) | 2016-08-18 | 2020-01-07 | Alkahest, Inc. | Blood plasma fractions as a treatment for aging-associated cognitive disorders |
| EP3504239B1 (en) | 2016-08-25 | 2024-05-29 | F. Hoffmann-La Roche AG | Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent |
| TW201825519A (zh) | 2016-10-18 | 2018-07-16 | 美商美國禮來大藥廠 | TGFβ受體II抗體 |
| WO2018115051A1 (en) * | 2016-12-22 | 2018-06-28 | F. Hoffmann-La Roche Ag | Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment |
| WO2018144334A1 (en) | 2017-02-02 | 2018-08-09 | Imclone Llc | Dosing regimen for anti-csf-1r antibody |
| WO2018183366A1 (en) | 2017-03-28 | 2018-10-04 | Syndax Pharmaceuticals, Inc. | Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy |
| CA3058944A1 (en) | 2017-04-19 | 2018-10-25 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| US11040068B2 (en) | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
| UA127828C2 (uk) | 2017-04-26 | 2024-01-17 | Алкахест, Інк. | Спосіб застосування фракції білків плазми крові для лікування когнітивних порушень |
| JP7537874B2 (ja) | 2017-05-19 | 2024-08-21 | シンダックス ファーマシューティカルズ， インコーポレイテッド | 併用療法 |
| BR112020003533A2 (pt) | 2017-08-25 | 2020-11-17 | Five Prime Therapeutics, Inc. | anticorpos b7-h4 e métodos de uso dos mesmos |
| BR112020004879A2 (pt) | 2017-09-13 | 2020-09-15 | Five Prime Therapeutics, Inc. | métodos para tratar o câncer pancreático, para tratar o câncer e para determinar a responsividade de um sujeito com câncer |
| US20200377571A1 (en) | 2017-12-08 | 2020-12-03 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
| CN111741978A (zh) | 2018-02-21 | 2020-10-02 | 戊瑞治疗有限公司 | B7-h4抗体制剂 |
| GB201803226D0 (en) * | 2018-02-28 | 2018-04-11 | Ultrahuman Twelve Ltd | CSF1R Binding agents |
| EP3759142A1 (en) | 2018-03-02 | 2021-01-06 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
| BR112020018709A2 (pt) * | 2018-03-28 | 2021-01-05 | Bristol-Myers Squibb Company | Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso |
| BR112020023746A2 (pt) * | 2018-05-23 | 2021-02-17 | Beigene, Ltd. | anticorpo, composição farmacêutica, método para tratar câncer, ácido nucleico isolado, vetor, célula hospedeira, processo para a produção de um anticorpo e reagente de diagnóstico |
| CN109096397B (zh) * | 2018-07-18 | 2019-04-16 | 博奥信生物技术（南京）有限公司 | 一种抗人csf-1r单克隆抗体及应用 |
| CN108948200B (zh) * | 2018-07-18 | 2019-05-10 | 博奥信生物技术（南京）有限公司 | 一种抗人csf-1r单克隆抗体及其应用 |
| CN108948201B (zh) * | 2018-07-18 | 2019-05-07 | 博奥信生物技术（南京）有限公司 | 抗人csf-1r单克隆抗体及应用 |
| KR20210049106A (ko) | 2018-07-27 | 2021-05-04 | 알렉터 엘엘씨 | 항-siglec-5 항체 및 이의 사용 방법 |
| WO2020069372A1 (en) | 2018-09-27 | 2020-04-02 | Elstar Therapeutics, Inc. | Csf1r/ccr2 multispecific antibodies |
| CA3115308A1 (en) | 2018-10-26 | 2020-04-30 | Alkahest, Inc. | Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery |
| EP3894014A4 (en) * | 2018-12-13 | 2022-04-20 | Development Center for Biotechnology | Anti-human csf-1r antibody and uses thereof |
| US20220137054A1 (en) * | 2019-03-05 | 2022-05-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New biomarkers and biotargets in renal cell carcinoma |
| WO2020232051A1 (en) * | 2019-05-15 | 2020-11-19 | Biosion Inc. | Antibody binding csf-1r and use thereof |
| AU2020283742A1 (en) * | 2019-05-24 | 2021-09-16 | Elixiron Immunotherapeutics (hong Kong) Limited | Anti-CSF1R antibodies, IL10 fusion proteins, and uses thereof |
| CN110499295A (zh) * | 2019-09-11 | 2019-11-26 | 宝船生物医药科技(上海)有限公司 | 一种csf-1r报告基因细胞株及其制备方法和应用 |
| WO2021058718A1 (en) | 2019-09-26 | 2021-04-01 | Roche Diagnostics Gmbh | Anti-csf-1r antibody |
| WO2021076942A1 (en) * | 2019-10-17 | 2021-04-22 | National Health Research Institutes | Use of succinate as biomarker in diagnosis and treatment of cancers |
| WO2021087105A1 (en) | 2019-10-30 | 2021-05-06 | Duke University | Immunotherapy with combination therapy comprising an immunotoxin |
| EP4073100A4 (en) | 2019-12-09 | 2024-02-14 | Syndax Pharmaceuticals, Inc. | ANTIBODIES FOR TREATING CHRONIC GRAFT VERSUS HOST DISEASE |
| KR102373965B1 (ko) * | 2020-06-05 | 2022-03-15 | (주)지아이이노베이션 | Ｉｌ-２ 단백질 및 ｃｄ８０ 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물 |
| CN115806626B (zh) * | 2022-06-21 | 2024-02-23 | 四川大学华西医院 | 一种基于csf1的嵌合抗原受体免疫细胞制备及其应用 |
| WO2024238787A1 (en) | 2023-05-17 | 2024-11-21 | Syndax Pharmaceuticals, Inc. | Methods of treating chronic graft-versus-host disease-related bronchiolitis obliterans syndrome using an anti-colony stimulating factor 1 receptor antibody |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
| JPH02503867A (ja) | 1988-04-15 | 1990-11-15 | プロテイン デザイン ラブズ インコーポレーテッド | Ｉｌ‐２レセプター特異的キメラ抗体 |
| ES2070172T3 (es) | 1988-04-16 | 1995-06-01 | Celltech Ltd | Procedimiento para producir proteinas mediante adn recombinante. |
| JPH0967400A (ja) | 1995-08-31 | 1997-03-11 | Toray Ind Inc | モノクローナル抗体、該抗体を産生するハイブリドーマ及びその利用 |
| EP1572106B1 (en) * | 2002-11-15 | 2010-05-05 | Novartis Vaccines and Diagnostics, Inc. | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| WO2006096461A2 (en) | 2005-03-08 | 2006-09-14 | Pharmacia & Upjohn Company Llc | Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent |
| MX2010001918A (es) * | 2007-08-21 | 2010-03-11 | Amgen Inc | Proteinas enlazadas al antigeno humano de celula de cepa mcdonough de felino. |
| CN101970496B (zh) * | 2008-03-14 | 2014-04-16 | 特朗斯吉有限公司 | 针对csf-1r的抗体 |
-
2011
- 2011-03-21 AR ARP110100905A patent/AR080698A1/es unknown
- 2011-03-22 JO JOP/2011/0097A patent/JO3291B1/ar active
- 2011-03-25 TW TW100110442A patent/TWI402078B/zh not_active IP Right Cessation
- 2011-03-28 RS RS20170817A patent/RS56219B1/sr unknown
- 2011-03-28 EP EP11713416.3A patent/EP2552966B1/en active Active
- 2011-03-28 BR BR112012024564A patent/BR112012024564A2/pt not_active Application Discontinuation
- 2011-03-28 MX MX2012011234A patent/MX2012011234A/es active IP Right Grant
- 2011-03-28 JP JP2013502691A patent/JP5767310B2/ja not_active Expired - Fee Related
- 2011-03-28 KR KR1020127025707A patent/KR101439719B1/ko not_active Expired - Fee Related
- 2011-03-28 DK DK11713416.3T patent/DK2552966T3/en active
- 2011-03-28 AU AU2011232850A patent/AU2011232850B2/en not_active Ceased
- 2011-03-28 PL PL11713416T patent/PL2552966T3/pl unknown
- 2011-03-28 HR HRP20171153TT patent/HRP20171153T1/hr unknown
- 2011-03-28 CN CN201180017294.3A patent/CN102834414B/zh not_active Expired - Fee Related
- 2011-03-28 WO PCT/US2011/030148 patent/WO2011123381A1/en not_active Ceased
- 2011-03-28 EA EA201270732A patent/EA021600B1/ru not_active IP Right Cessation
- 2011-03-28 UA UAA201210763A patent/UA111818C2/uk unknown
- 2011-03-28 HU HUE11713416A patent/HUE036379T2/hu unknown
- 2011-03-28 NZ NZ602621A patent/NZ602621A/en not_active IP Right Cessation
- 2011-03-28 SI SI201131235T patent/SI2552966T1/sl unknown
- 2011-03-28 CA CA2795081A patent/CA2795081C/en not_active Expired - Fee Related
- 2011-03-28 SG SG2012064135A patent/SG183829A1/en unknown
- 2011-03-28 US US13/073,004 patent/US8263079B2/en not_active Expired - Fee Related
- 2011-03-28 ES ES11713416.3T patent/ES2640909T3/es active Active
- 2011-03-28 ME MEP-2017-174A patent/ME02806B/me unknown
- 2011-03-28 LT LTEP11713416.3T patent/LT2552966T/lt unknown
- 2011-03-28 EP EP16196811.0A patent/EP3156419A1/en not_active Withdrawn
- 2011-03-28 PT PT117134163T patent/PT2552966T/pt unknown
-
2012
- 2012-09-14 ZA ZA2012/06926A patent/ZA201206926B/en unknown
- 2012-09-27 IL IL222222A patent/IL222222A/en not_active IP Right Cessation
-
2017
- 2017-09-07 CY CY20171100949T patent/CY1119324T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013529183A5 (enExample) | ||
| IL302078A (en) | Anti-ccr8 monoclonal antibodies and uses thereof | |
| ME02806B (me) | Protutijela protiv csf-1r | |
| AU2013327116B2 (en) | Combination of anti-KIR antibodies and anti-PD-1 antibodies to treat cancer | |
| JP2008500815A5 (enExample) | ||
| JP2014530215A5 (enExample) | ||
| JP2019536806A5 (enExample) | ||
| RU2019102009A (ru) | Специфические антитела к pd-l1 и способы их применения | |
| RU2016122041A (ru) | Новые анти-клаудин антитела и способы их применения | |
| JP2009102444A5 (ja) | 二次性骨腫瘍の治療のための抗PDGFRα抗体 | |
| JP2015535828A5 (enExample) | ||
| CL2010001544A1 (es) | Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma. | |
| JP2012523417A5 (enExample) | ||
| JP2015517300A5 (enExample) | ||
| JP2015532292A5 (enExample) | ||
| JP2019535254A5 (ja) | 抗ｐｄ−ｌ１抗体および変異型 | |
| JP2018504105A5 (enExample) | ||
| JP2011157397A5 (enExample) | ||
| JP2017529838A5 (enExample) | ||
| JP2013522237A5 (enExample) | ||
| JP2012500814A5 (enExample) | ||
| IL273841B1 (en) | Antibodies targeting cd137 and methods of use thereof | |
| NZ603972A (en) | Anti-fgfr2 antibodies | |
| RU2018124319A (ru) | Новые антитела к клаудину и способы их применения | |
| NZ610153A (en) | Novel anti-dr5 antibody |